Which of the following is a potential therapeutic effect of Atropine in asthma patients?

Atropine is an anticholinergic agent that helps in relaxing bronchial smooth muscle, which can be beneficial for patients experiencing bronchospasm, such as those with asthma. One of the therapeutic effects of Atropine is its ability to lessen bronchospasm triggered by airway manipulation. This is particularly relevant during procedures where the airway may be stimulated or irritated, leading to increased bronchoconstriction. By inhibiting the action of acetylcholine on muscarinic receptors, Atropine reduces mucus secretion and helps to prevent or mitigate the bronchospasm, making it easier for patients to breathe.

The other options focus on effects that would not be therapeutic in the context of asthma treatment. For example, increasing mucus production could lead to further airway obstruction, enhancing bronchoconstriction is contrary to the desired outcome in managing asthma, and reducing oxygen saturation would indicate worsening respiratory function rather than improvement. Therefore, the primary benefit of Atropine in asthma patients is its potential to reduce bronchospasm during situations that may provoke exacerbations.